Compare OVLY & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVLY | PBYI |
|---|---|---|
| Founded | 1990 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.7M | 263.4M |
| IPO Year | N/A | N/A |
| Metric | OVLY | PBYI |
|---|---|---|
| Price | $33.13 | $6.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 15.7K | ★ 441.5K |
| Earning Date | 01-23-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.26% | N/A |
| EPS Growth | N/A | ★ 59.87 |
| EPS | ★ 2.88 | 0.74 |
| Revenue | $80,924,000.00 | ★ $211,995,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.52 | ★ $8.88 |
| Revenue Growth | ★ 3.47 | N/A |
| 52 Week Low | $22.70 | $2.58 |
| 52 Week High | $34.00 | $7.29 |
| Indicator | OVLY | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 66.29 | 53.21 |
| Support Level | $31.66 | $6.75 |
| Resistance Level | $34.00 | $6.98 |
| Average True Range (ATR) | 0.55 | 0.32 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 69.81 | 35.61 |
Oak Valley Bancorp is a bank holding company that operates through Oak Valley Community Bank (the Bank). The Bank offers a complement of business checking and savings accounts for its business customers. The Bank also offers commercial and real estate loans, as well as lines of credit. In addition, the bank provides other services for both individuals and businesses including online banking, remote deposit capture, mobile banking, merchant services, night depository, extended hours, wire transfer of funds, note collection, and automated teller machines in a national network. Its primary source of revenue is net interest income.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.